The first of several patents filed by Vicus on combinations for treatment of cancer-induced systemic inflammation was published on February 8, 2008 entitled “Drug combination pharmaceutical compositions and methods for using them”. http://www.wipo.int/pctdb/en/wo.jsp?wo=2008014471&IA=WO2008014471
Clinical Trials
Vicus Therapeutics has recently completed a multi-center, randomized, open-label, controlled, Phase 2 trial of VT-122 in 37 weight losing subjects with advanced lung cancer. The Final Study Report was filed in March 2009. Based on positive results of the Phase 2 trial, Vicus is currently planning additional studies in combination with leading targeted oncology drug products for the treatment of advanced lung and other cancers.
